ICE was established in 1997 as a trader of pharmaceutical raw materials by David Bilton, former Vice President of Global Outsourcing for Smithkline Beecham. The company sought to benefit from the increasing interest in Indian and Chinese API suppliers, capitalising on its experience of trading in the East achieving early success with generic suppliers, and launching multiple major molecules.
Building on a network of close client relationships, and their continuing success, ICE diversified into finished dose contract manufacturing and the trading of pharmaceutical registration dossiers and licenses.
During the mid 2000's, as the industry consolidated, the company made a strategic move away from trading. Establishing a network of carefully matched partnerships and joint ventures, ICE progressed to become an independent supplier, no longer working as an intermediary.
The latest development in the business has been to take on its own products and to capitalise on the global licensing network, in effect, becoming an independent generics company with a strong focus on manufacture in the Far East. As the company grew and the areas of business focus increased, the company restructured in 2008, to become ICE Pharma Group, comprising three major commercial divisions: ICE Pharma, ICE Formulations and ICE Healthcare currently employing approximately 20 staff and forecasting exponential growth.